|
|
|
|
LEADER |
03183nam a2200457 4500 |
001 |
on1012850681 |
003 |
OCoLC |
005 |
20180501122038.0 |
006 |
m d |
007 |
cr |n||||||||| |
008 |
171124s2017 maua o 001 0 eng d |
040 |
|
|
|a IDEBK
|b eng
|e rda
|c IDEBK
|d N$T
|d OPELS
|d EBLCP
|d YDX
|d N$T
|d NLE
|d OCLCF
|d MEU
|d SAV
|d GrThAP
|
019 |
|
|
|a 1013498870
|
020 |
|
|
|a 9780128130698
|
035 |
|
|
|a (OCoLC)1012850681
|z (OCoLC)1013498870
|
050 |
|
4 |
|a RM301.25
|b .P53 2017eb
|
072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
082 |
0 |
4 |
|a 615.1/9
|2 23
|
049 |
|
|
|a TEFA
|
245 |
0 |
0 |
|a Platform Technologies in Drug Discovery and Validation /
|c edited by Robert A. Goodnow.
|
264 |
|
1 |
|a Cambridge :
|b Academic Press,
|c 2017.
|
300 |
|
|
|a 1 online resource (xiv, 657 pages :
|b illustrations).
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Annual reports in medicinal chemistry ;
|v v. 50
|
546 |
|
|
|a Text in English.
|
500 |
|
|
|a Includes indexes.
|
588 |
|
|
|a Description based on print version record.
|
505 |
0 |
|
|a DNA-Encoded Library Technology: a Brief Guide to its Evolution and Impact on Drug Discovery -- The Chemistry of Oligonucleotide Delivery -- CRISPR-Cas9 for Drug Discovery in Oncology -- Recent Advances of Microfluidics Technologies in the Field of Medicinal Chemistry -- High-Throughput Screening -- Kinase-Centric Computational Drug Development -- Free Energy Calculation Guided Virtual Screening of Synthetically Feasible Ligand R-Group and Scaffold Modifications: An Emerging Paradigm for Lead Optimization -- Phenotypic Screening -- Targeted Protein Degradation -- Chemical Biology in Drug Discovery -- Fragment-Based Lead Discovery -- Antibody-Drug Conjugates -- Antibody-Recruiting Small Molecules: Synthetic Constructs as Immunotherapeutics -- A Decade of Deuteration in Medicinal Chemistry -- From Natural Peptides to Market.
|
520 |
|
|
|a "Platform Technologies in Drug Discovery and Validation, Volume 50, the latest release in the Annual Reports in Medicinal Chemistry series, provides timely and critical reviews of important topics in medicinal chemistry, with an emphasis on emerging topics in the biological sciences. Topics covered in this new volume include DELT, Oligos: ASO, siRNA, CRISPR, Micro-fluidic chemistry, High throughput screening, Kinase-centric computational drug development, Virtual Screening, Phenotypic screening, PROTACS, Chemical Biology, Fragment-based lead generation, Antibody-Drug Conjugates, Antibody-recruiting small molecules, Deuteration, and Peptides."--Publisher.
|
650 |
|
0 |
|a Drug development.
|
650 |
|
0 |
|a Pharmaceutical technology.
|
650 |
|
7 |
|a MEDICAL / Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a Drug development.
|2 fast
|0 (OCoLC)fst00898670
|
650 |
|
7 |
|a Pharmaceutical technology.
|2 fast
|0 (OCoLC)fst01060211
|
655 |
|
4 |
|a Electronic books.
|
700 |
1 |
|
|a Goodnow, Robert A.,
|c Jr.,
|e editor.
|
776 |
0 |
8 |
|c Original
|z 9780128130698
|z 0128130695
|w (OCoLC)988300259
|
830 |
|
0 |
|a Annual reports in medicinal chemistry ;
|v v. 50.
|
856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/00657743/50
|z Full Text via HEAL-Link
|